HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Competing interest statement All Versions of this Article: gut.2005.070896v1 54/11/1573    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Staa, T P Articles by Leufkens, H G M Search for Related Content PubMed PubMed Citation Articles by van Staa, T P Articles by Leufkens, H G M Topic Collections Relevant Articles

5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study

¹ Department of Pharmacoepidemiology and Pharmacotherapy, University of Utrecht,, Utrecht, the Netherlands, and Procter and Gamble Pharmaceuticals, Egham, UK
² Division of Epidemiology and Public Health, University of Nottingham Medical School, Nottingham, UK
³ Department of Pharmacoepidemiology and Pharmacotherapy, University of Utrecht, Utrecht, the Netherlands

Correspondence to:
Correspondence to:
Professor R F Logan
Division of Epidemiology and Public Health, School of Community Health Sciences, University of Nottingham Medical School, Nottingham NG7 2UH, UK; richard.logan{at}nottingham.ac.uk

Background and aims: The objective of this study was to evaluate the risk of colorectal cancer (CRC) in patients taking aminosalicylates (5-ASA) for inflammatory bowel disease (IBD).

Methods: The General Practice Research Database (GPRD) which contains the primary care records of five million people in the UK was used to identify users of mesalazine, balsalazide, olsalazine, or sulfasalazine with a history of IBD. In a nested case control analysis, each incident CRC case with any use of a 5-ASA in the six months before the CRC diagnosis was matched by age, sex, and calendar time to six control patients who were also currently using a 5-ASA. Patients were then classified according to regularity of use. The analysis was controlled for body mass index, IBD duration, history of colorectal polyps, use of non-steroidal anti-inflammatory drugs, paracetamol, aspirin, immunosuppressants, oral and rectal glucocorticoids, prior gastrointestinal hospitalisation, recorded colonoscopy, and number of visits to the general practitioner for IBD symptoms in the 6–24 months before diagnosis.

Results: The study population included 18 969 patients, of whom 100 had developed CRC during 5-ASA exposure. Most of these cases had a history of ulcerative colitis (76 patients). In the case control analysis, regular users, defined as having six or more 5-ASA prescriptions in the previous 12 months, were found to have a decreased risk of CRC compared with irregular users (crude odds ratio (OR) 0.7 (0.44–1.03); adjusted OR 0.60 (0.38–0.96)). Regular users of sulfasalazine with 6–12 prescriptions before had an adjusted OR of 0.95 (0.22–4.11); with 13–30 prior prescriptions this was 0.41 (0.14–1.20) and with >30 prior prescriptions this was 0.77 (0.37–1.60). For mesalazine users, these values were 1.13 (0.49–2.59), 0.30 (0.11–0.83), and 0.31 (0.11–0.84), respectively.

Conclusion: These results show that regular 5-ASA use is associated with some reduction in the risk of CRC developing in ulcerative colitis.

Abbreviations: 5-ASA, 5-aminosalicylate; CRC, colorectal cancer; NSAIDs, non-steroidal anti-inflammatory drugs; IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn’s disease; GPRD, General Practice Research Database; OR, odds ratio; RR, relative rate; RA, rheumatoid arthritis

Keywords: Crohn’s disease; ulcerative colitis; inflammatory bowel disease; colorectal cancer; 5-aminosalicylate

Relevant Articles

JournalScan
Gut 2007 56: 283. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				K. Hemminki, X. Li, J. Sundquist, and K. Sundquist Cancer risks in Crohn disease patients Ann. Onc., September 2, 2008; (2008) mdn595v1. [Abstract] [Full Text] [PDF]

				M. Schwab, V. Reynders, S. Loitsch, Y. M. Shastri, D. Steinhilber, O. Schroder, and J. Stein PPAR{gamma} is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells Carcinogenesis, July 1, 2008; 29(7): 1407 - 1414. [Abstract] [Full Text] [PDF]

				C. Stolfi, D. Fina, R. Caruso, F. Caprioli, M. C. Fantini, A. Rizzo, M. Sarra, F. Pallone, and G. Monteleone Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase Carcinogenesis, June 1, 2008; 29(6): 1258 - 1266. [Abstract] [Full Text] [PDF]

				T Kitiyakara and R W Chapman Chemoprevention and screening in primary sclerosing cholangitis Postgrad. Med. J., May 1, 2008; 84(991): 228 - 237. [Abstract] [Full Text] [PDF]

				S. Y. Nam, J. S. Kim, J. M. Kim, J. Y. Lee, N. Kim, H. C. Jung, and I. S. Song DA-6034, a Derivative of Flavonoid, Prevents and Ameliorates Dextran Sulfate Sodium-Induced Colitis and Inhibits Colon Carcinogenesis Experimental Biology and Medicine, February 1, 2008; 233(2): 180 - 191. [Abstract] [Full Text] [PDF]

				J. F. Di Mari, J. I. Saada, R. C. Mifflin, J. D. Valentich, and D. W. Powell HETEs enhance IL-1-mediated COX-2 expression via augmentation of message stability in human colonic myofibroblasts Am J Physiol Gastrointest Liver Physiol, October 1, 2007; 293(4): G719 - G728. [Abstract] [Full Text] [PDF]

eLetters: